celecoxib has been researched along with Liver Steatosis in 7 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Previous studies have demonstrated that the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib shows efficacy against multiple cancers, including hepatocellular carcinoma." | 7.91 | Celecoxib alleviates AKT/c-Met-triggered rapid hepatocarcinogenesis by suppressing a novel COX-2/AKT/FASN cascade. ( Chen, L; Deng, X; Hu, J; Li, X; Qiu, Z; Sheng, L; Zhang, C; Zheng, G; Zhou, J, 2019) |
| "We investigated the effects of metformin and celecoxib on obesity-induced adipose tissue inflammation, insulin resistance (IR), fatty liver, and high blood pressure in high-fat (HF) fed rats." | 7.83 | Additional effect of metformin and celecoxib against lipid dysregulation and adipose tissue inflammation in high-fat fed rats with insulin resistance and fatty liver. ( Hsieh, PS; Hung, YJ; Lu, CH, 2016) |
| "Ethanol treatment caused liver steatosis, moderate cellular infiltration and enhanced levels of plasma alanine transaminase (ALT) and tumour necrosis factor-alpha (TNF-alpha)." | 5.33 | Chronic effects of celecoxib, a cyclooxygenase-2 inhibitor, cause enhanced alcohol-induced liver steatosis in rats. ( Bykov, IL; Lindros, KO; Palmen, M; Rainsford, KD, 2006) |
| "Previous studies have demonstrated that the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib shows efficacy against multiple cancers, including hepatocellular carcinoma." | 3.91 | Celecoxib alleviates AKT/c-Met-triggered rapid hepatocarcinogenesis by suppressing a novel COX-2/AKT/FASN cascade. ( Chen, L; Deng, X; Hu, J; Li, X; Qiu, Z; Sheng, L; Zhang, C; Zheng, G; Zhou, J, 2019) |
| "We investigated the effects of metformin and celecoxib on obesity-induced adipose tissue inflammation, insulin resistance (IR), fatty liver, and high blood pressure in high-fat (HF) fed rats." | 3.83 | Additional effect of metformin and celecoxib against lipid dysregulation and adipose tissue inflammation in high-fat fed rats with insulin resistance and fatty liver. ( Hsieh, PS; Hung, YJ; Lu, CH, 2016) |
| "The underlying mechanisms of nonalcoholic steatohepatitis (NASH) are poorly understood, and little is known about hepatocellular apoptosis in NASH." | 1.39 | Cyclooxygenase-2 promotes hepatocellular apoptosis by interacting with TNF-α and IL-6 in the pathogenesis of nonalcoholic steatohepatitis in rats. ( Chen, M; Cheng, Q; Huang, C; Li, N; Qian, Z; Shi, G; Wang, X; Xu, S; Zheng, J, 2013) |
| "In conclusion, GnT-V prevented steatohepatitis progression through modulating lymphocyte and HSC functions." | 1.38 | N-Acetylglucosaminyltransferase V regulates TGF-β response in hepatic stellate cells and the progression of steatohepatitis. ( Hiramatsu, N; Ishii, M; Kamada, Y; Kawada, N; Kiso, S; Matsumoto, H; Miyoshi, E; Mori, K; Moriwaki, K; Shinzaki, S; Takehara, T; Yoshida, Y, 2012) |
| "Body weight was increased significantly and similarly in HFa, HFa-Cel, and HFa-Mes." | 1.35 | COX-2-mediated inflammation in fat is crucial for obesity-linked insulin resistance and fatty liver. ( Chan, PC; Chen, CH; Chiang, CF; Hsieh, PS; Jin, JS; Shih, KC, 2009) |
| "Ethanol treatment caused liver steatosis, moderate cellular infiltration and enhanced levels of plasma alanine transaminase (ALT) and tumour necrosis factor-alpha (TNF-alpha)." | 1.33 | Chronic effects of celecoxib, a cyclooxygenase-2 inhibitor, cause enhanced alcohol-induced liver steatosis in rats. ( Bykov, IL; Lindros, KO; Palmen, M; Rainsford, KD, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Qiu, Z | 1 |
| Zhang, C | 1 |
| Zhou, J | 1 |
| Hu, J | 1 |
| Sheng, L | 1 |
| Li, X | 2 |
| Chen, L | 1 |
| Deng, X | 1 |
| Zheng, G | 1 |
| Cheng, Q | 1 |
| Li, N | 1 |
| Chen, M | 1 |
| Zheng, J | 1 |
| Qian, Z | 1 |
| Wang, X | 1 |
| Huang, C | 1 |
| Xu, S | 1 |
| Shi, G | 1 |
| Tian, F | 1 |
| Zhang, YJ | 1 |
| Li, Y | 1 |
| Xie, Y | 1 |
| Lu, CH | 1 |
| Hung, YJ | 1 |
| Hsieh, PS | 2 |
| Jin, JS | 1 |
| Chiang, CF | 1 |
| Chan, PC | 1 |
| Chen, CH | 1 |
| Shih, KC | 1 |
| Kamada, Y | 1 |
| Mori, K | 1 |
| Matsumoto, H | 1 |
| Kiso, S | 1 |
| Yoshida, Y | 1 |
| Shinzaki, S | 1 |
| Hiramatsu, N | 1 |
| Ishii, M | 1 |
| Moriwaki, K | 1 |
| Kawada, N | 1 |
| Takehara, T | 1 |
| Miyoshi, E | 1 |
| Bykov, IL | 1 |
| Palmen, M | 1 |
| Rainsford, KD | 1 |
| Lindros, KO | 1 |
7 other studies available for celecoxib and Liver Steatosis
| Article | Year |
|---|---|
Celecoxib alleviates AKT/c-Met-triggered rapid hepatocarcinogenesis by suppressing a novel COX-2/AKT/FASN cascade.
Topics: Animals; Apoptosis; Carcinogenesis; Carcinoma, Hepatocellular; Celecoxib; Cell Proliferation; Cycloo | 2019 |
Cyclooxygenase-2 promotes hepatocellular apoptosis by interacting with TNF-α and IL-6 in the pathogenesis of nonalcoholic steatohepatitis in rats.
Topics: Animals; Apoptosis; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diet, High-Fat; Diseas | 2013 |
Celecoxib ameliorates non-alcoholic steatohepatitis in type 2 diabetic rats via suppression of the non-canonical Wnt signaling pathway expression.
Topics: Animals; Biomarkers; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diabetes Mellitus, Ty | 2014 |
Additional effect of metformin and celecoxib against lipid dysregulation and adipose tissue inflammation in high-fat fed rats with insulin resistance and fatty liver.
Topics: Adipocytes; Adipokines; Adipose Tissue; AMP-Activated Protein Kinases; Animals; Blood Pressure; Body | 2016 |
COX-2-mediated inflammation in fat is crucial for obesity-linked insulin resistance and fatty liver.
Topics: Adipocytes; Adipogenesis; Adipose Tissue; Animals; Blood Glucose; Body Weight; Celecoxib; Cell Size; | 2009 |
N-Acetylglucosaminyltransferase V regulates TGF-β response in hepatic stellate cells and the progression of steatohepatitis.
Topics: Animals; Celecoxib; Cyclooxygenase 2; Fatty Liver; Hepatic Stellate Cells; Male; Mice; Mice, Transge | 2012 |
Chronic effects of celecoxib, a cyclooxygenase-2 inhibitor, cause enhanced alcohol-induced liver steatosis in rats.
Topics: Alanine Transaminase; Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, D | 2006 |